The trial testing the immune response of co-administration of GSK's blockbuster vaccines, Shingrix and Arexvy, in adults over 50 years of age, met the main goal of the study. Sign up here.

"A regulatory decision by the FDA on this submission is expected in H1 2026. GSK is continuing to seek expanded indications for its RSV vaccine in other geographies including in the European Economic ...

Your immune system never develops a memory for RSV. About 50% of infants can be reinfected with RSV two months after the initial infection. That's shocking to me.

GSK (NYSE:GSK) reported its RSV vaccine Arexvy elicited a robust immune response in recipients aged 18 to 49 years who were at increased risk of developing lower respiratory tract disease as a ...

Immune responses to respiratory syncytial virus (RSV) vaccines tended to fall short in older people with weakened immunity, a study found. In 38 immunocompromised persons who received either the ...

Pfizer’s (NYSE:PFE) respiratory syncytial virus (RSV) vaccine Abrysvo was well-tolerated and generated strong neutralizing responses after a single dose in a late-stage study of adults aged 18 ...

COVID-19 linked to more severe outcomes than flu, RSV in 2022-2023 season; Budget proposal called ‘slap in the face’ to older adults, caregivers ...

A dose of Pfizer’s respiratory syncytial virus vaccine was well tolerated and generated a strong immune response among adults aged 59 years or younger, the company announced in a press release.

So when RSV prevents interferon from communicating to these genes the virus slams the brakes on our immune response, which can result in the virus taking hold and quite quickly causing very ...

Scientists have discovered how the dangerous Respiratory Syncytial Virus (RSV) defuses our immune response and, in doing so, they have pinpointed an exciting new target for drug developers. Irish ...

Your immune system never develops a memory for RSV. About 50% of infants can be reinfected with RSV two months after the initial infection. That's shocking to me.

The trial testing the immune response of co-administration of GSK's blockbuster vaccines, Shingrix and Arexvy, in adults over 50 years of age, met the main goal of the study. The co-administration ...